Route-specific safety
GHK-Cu
FDA’s warning concerns injectable use. Keep product types and routes separate.
No dosing or purchase guidance. This information is not a recommendation to use a compound.
The route of use matters.
FDA identifies potential immunogenicity risks for compounded injectable GHK-Cu related to aggregation and peptide impurities. It says human data are limited for assessing safety.
The agency’s entry is specifically about injectable routes of administration. It should not be treated as a clinical evaluation of every topical cosmetic carrying a similar name.
This page does not establish that a topical or injectable product is effective or suitable for a particular person. Product claims, ingredient names and route of use need separate review.
Original source
Interpretation is limited to the source linked above. Independent medical review pending.